Thank you for joining me today to learn about how TEG6S can be utilized within #Anesthesiology. Let's recap on some of the topics that we learned such as specimen collection and transportation, test components, interpretations and more.
👇🏽Follow the #tweetorial below.
First, we reviewed concepts of hemostasis.
Imagine that you cut your hand on a sharp piece of glass, ouch😲
After vasoconstriction, endothelial injury leads to PLT adhesion & aggregation --> the PLT plug.
Release of tissue factor activates coagulation cascade -->fibrin clot
Although we learn these pathways as if they happen sequentially, they are really happening simultaneously. 🔄Platelets are activated by thrombin formation, thrombin formation is activated by platelets.
⁉️What are the traditional coag labs?
🧪That's right. Traditional coagulation testing (PT/PTT) involves plasma based assays that only examine the coagulation factor portion of hemostasis. This doesn't always reflect the patient's TRUE clot or bleeding potential...
👋🏽On the other hand, viscoelastic testing assesses BOTH the cellular + plasma coagulation factor interactions visualizing the ENTIRE clotting process from initiation to lysis. It's primarily used to personalize transfusion management and patient care.
I'm really excited that we have implemented @HaemoneticsCorp TEG6S within @SSMHealthSTL Core Lab area.
This analyzer, developed for point of care testing, is simple and automated and allows for 4 separate tests to be run at one time.
👇🏽Check out this clean & simple design below.
Remember that we have 3 cartridges to run 3 tests
☑️Global hemostasis
☑️Global hemostasis with lysis
✅Platelet Mapping
The samples should be collected using a 21 gauge needle, place tubes in the designated collection bag and send through the pneumatic tube system.
🦶🏽Let's walk through the components of the cartridges...
R value is the time it takes initiate a clot and is measured in minutes.
When prolonged, this can be a sign of bleeding secondary to a factor deficiency and the need to transfuse FFP.
Maximal Amplitude (MA), measured in mm, is the value that describes the clot strength at is maximum potential.
MA CRT: Clot strength with both platelets (80%) and fibrinogen (20%) contribution.
MA FF: Clot strength determined by fibrinogen contribution.
Lysis % 30 (LY30) describes the clot stability describing the fibrinolytic phase, or clot breakdown. If LY30 is increased then we have hyperfibrinolysis. This value is particularly important in the trauma setting when the goal is to STOP the bleed and from and maintain a clot.
To learn more about the topic of viscoelastic testing, I highly recommend reading this great article from @AABB 𝗧𝗿𝗮𝗻𝘀𝗳𝘂𝘀𝗶𝗼𝗻 Journal written by @TimCarll and Dr. Geoff Wool 👉🏽Basic principles of viscoelastic testing. onlinelibrary.wiley.com/doi/10.1111/tr…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Thank you for joining me to today for the @SSMHealthSTL Pediatric Education Webinar Series where we discussed the topic of 🩸👶🏾Pediatric Patient Blood Management.
From our rural hospitals to large academic ones, together let's optimize pediatric & neonatal care.
👇🏽 #Blooducation
Coming out of #WorldBloodDonorDay, it was perfect timing to discuss this topic as we celebrate our incredible blood donors while bringing awareness of the need to collect and transfuse safe blood to our patients, many which are so 🖐️🏽tiny, fitting within the palm of our hand.
💎Blood is a precious resource.
⚖️Blood transfusions have risks.
"Transfusing the right product, in the right dose, to the right patient, at the right time" is the fundamental concept of Patient Blood Management.
How do we apply these concepts within the pediatric setting?
🌟Just released! Outstanding @bloodbankguy 🎧podcast w/ Dr. Sujit Sheth. Comprehensive discussion on transfusion-dependent #thalassemia focusing on pathogenesis, terminology & role of transfusion support. Listen now for CE credit.
For the pearls, follow the #Tweetorial below👇🏽
Derived from the Greek word “thal” or sea🌊thalassemia known as Mediterranean anemia, is an anemia affecting 1.5% of the world population along the “thalassemia belt” extending from the Mediterranean, the Middle East, India, SoutheastAsia, up to China. Like SCD, thalassemias are:
Thalassemias are also hereditary and may offer protection against malaria. However, unlike #sicklecelldisease which results in qualitative Hb defects, thalassemia causes a quantitative defects in either Hb α or β chains causing both ineffective erythropoiesis and anemia.
🅰️🅱️🅾️🆎#Blooducation colleagues: Fantastic new @bloodbankguy 🎧podcast with Dr. Mark Yazer on the topic of Whole Blood in Trauma Resuscitation discussing benefits and safety, and review of many important published trials. Listen now --> BBGuy.org/091.
Dr. Yazer explains some major benefits of #wholeblood. Balanced resuscitation in just 👜ONE bag, making logistics so much easier. There are fewer donor exposures and less additives & anticoagulants. Additionally, cold stored platelets are "primed for coagulation activity"
In 2018, 31rst @AABB Standards indicates that the definition of “low titer” shall be made locally by each transfusion service, and that policy specifies which patients are eligible to receive whole blood, the maximum quantity of how to monitor for adverse events post transfusion.
A 1 day y/o 👶🏽neonate, born at 40 weeks, was transferred to our NICU for anemia & hyperbilirubinemia. He is jaundice but has no signs of encephalopathy.🩸The antibody screen is positive.
👇🏽Check out his peripheral smear below and notice the increased number of nucleated RBCs.
🤔Based on the peripheral smear findings, you begin to investigate the patient’s blood bank history because you are suspecting:
🙌🏽You got it! Based on the history and the peripheral smear findings, you are suspecting hemolytic disease of the fetus and newborn (#HDFN), which is when maternal antibodies are directed against fetal RBC antigens. What is the most common cause of #HDFN? #Blooducation
"My heart beats for patient collaboration and that's why I went in Transfusion Medicine...."
Important to know how to approach a #DonorLookBack which is a multistep process a blood establishment must complete as a response to a donor who is newly reactive for an infectious disease test. Check out @bloodbankguy for more information 👆🏼👉🏼 bbguy.org/education/glos…